Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03675360
Other study ID # 2018-053
Secondary ID P20GM109036
Status Completed
Phase N/A
First received
Last updated
Start date September 25, 2018
Est. completion date June 21, 2021

Study information

Verified date January 2023
Source Tulane University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed randomized controlled trial will test the effect of a low-carbohydrate diet on hemoglobin A1c among individuals with elevated hemoglobin A1c that are within the range of prediabetes or diabetes. Results may provide evidence about the role of carbohydrate restriction in individuals with or at high risk of type 2 diabetes.


Description:

In the short-term, among patients with type 2 diabetes, low-to-moderate carbohydrate diets have a greater glucose-lowering effect than do high-carbohydrate diets. However, compared with usual diet, the effect of a behavioral intervention promoting a low-carbohydrate/high-unsaturated fat and high-protein dietary pattern among individuals with prediabetes or untreated type 2 diabetes is not well understood. The overall goal of this randomized controlled trial is to study the effect of a behavioral intervention promoting a low-carbohydrate/high-unsaturated fat and high-protein dietary pattern compared with usual diet on hemoglobin A1c (HbA1c) and other metabolic risk factors among individuals with or at high risk of diabetes (HbA1c 6.0-6.9%). A total of 150 participants with HbA1c 6.0-6.9% will be recruited and randomly assigned to either a 6-month behavioral modification program designed to reduce carbohydrate intake (initial target <40 g digestible carbohydrates, final target <60 g digestible carbohydrates) or to usual diet in a 1:1 randomization ratio. The primary outcome will be the difference between the active intervention and control groups for change in HbA1c from baseline to 6 months. Secondary outcomes will be fasting glucose, systolic blood pressure, total-to-high-density lipoprotein-cholesterol ratio, and body weight. Findings from this study may provide evidence about the role of carbohydrate restriction in individuals with or at high risk of type 2 diabetes.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date June 21, 2021
Est. primary completion date June 21, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 70 Years
Eligibility Inclusion Criteria: - Men or women ages 40 to 70 years - HbA1c 6.0-6.9% - Willing and able to provide informed consent Exclusion Criteria: - Diagnosed type 1 diabetes mellitus - Use of agents affecting glycemic control (medications for diabetes, oral glucocorticoids) within the past three months prior to enrollment - Medical condition in which low-carbohydrate diet may not be advised: estimated glomerular filtration rate (eGFR) =45 mL/min/1.73 m²; self-report of liver disease due to hepatitis or alcohol; osteoporosis; untreated thyroid disease; gout; cancer (other than non-melanoma skin cancer) requiring treatment in the past year, unless prognosis is excellent - Factors that may affect HbA1c: hemoglobin <11 mg/dL (cutpoint for moderate-to-severe anemia, which could lead to falsely elevated or lowered HbA1c); recent blood donation or blood transfusion (self-report, past 4 months); human immunodeficiency virus (self-report) - Self-reported history of intensive care unit stay due to Coronavirus Disease 2019 (COVID-19) in the past three months, as severe COVID-19 may affect blood glucose levels - Allergies to nuts - For women, current pregnancy, breastfeeding, or plans to become pregnant during the study - Consumption of =21 alcoholic drinks per week or consumption of =6 drinks per occasion - Current or planned residence making it difficult to meet trial requirements (due to distance from study site and/or challenges regularly traveling to site) - Current participation in another lifestyle intervention trial or a pharmaceutical trial - Participation of another household member in the study; employees or persons living with employees of the study - Other concerns regarding ability to meet trial requirements, at the discretion of the principal investigator or study coordinator

Study Design


Intervention

Behavioral:
Low-Carbohydrate Diet
Behavioral modification to reduce carbohydrate consumption. Target <40 g net carbohydrates per day for first 3 months; <60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups. At baseline, participants will receive written information with standard physical activity recommendations.

Locations

Country Name City State
United States Tulane Office of Health Research New Orleans Louisiana

Sponsors (2)

Lead Sponsor Collaborator
Tulane University School of Public Health and Tropical Medicine National Institute of General Medical Sciences (NIGMS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Insulin 6-month change in fasting insulin comparing low-carbohydrate arm with usual diet arm Baseline and six months
Other Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) 6-month change in HOMA-IR comparing low-carbohydrate arm with usual diet arm. HOMA-IR was calculated as fasting insulin (µIU/mL) x fasting glucose (mmol/L)/22.5. Baseline and six months
Other Change in Diastolic Blood Pressure 6-month change in diastolic blood pressure comparing low-carbohydrate arm with usual diet arm Baseline and six months
Other Change in Waist Circumference 6-month change in waist circumference comparing low-carbohydrate arm with usual diet arm Baseline and six months
Other Change in Estimated Atherosclerotic Cardiovascular Disease Risk 6-month change in estimated 10-year atherosclerotic cardiovascular disease risk comparing low-carbohydrate arm with usual diet arm.
The estimated 10-year cardiovascular disease risk was assessed by 2013 American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Score, known as the Pooled Cohort Equations. The Pooled Cohort Equations estimate the 10-year primary risk of ASCVD (atherosclerotic cardiovascular disease) among patients without pre-existing cardiovascular disease who are between 40 and 79 years of age. Variables included in the risk score include: gender, age, race, total cholesterol, HDL cholesterol, systolic blood pressure, treatment for blood pressure, diabetes, and smoking status.
Reference: Goff DC, Lloyd-Jones DM et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines. Vol. 129, Circulation. 2014.
Baseline and six months
Primary Change in Hemoglobin A1c 6-month change in Hemoglobin A1c comparing low-carbohydrate arm with usual diet arm Baseline and six months
Secondary Change in Fasting Plasma Glucose 6-month change in fasting plasma glucose comparing low-carbohydrate arm with usual diet arm Baseline and six months
Secondary Change in Systolic Blood Pressure 6-month change in systolic blood pressure comparing low-carbohydrate arm with usual diet arm Baseline and six months
Secondary Change in Total-to-HDL-cholesterol Ratio 6-month change in total-to-HDL-cholesterol ratio comparing low-carbohydrate arm with usual diet arm Baseline and six months
Secondary Change in Body Weight 6-month change in body weight comparing low-carbohydrate arm with usual diet arm Baseline and six months
See also
  Status Clinical Trial Phase
Completed NCT05594446 - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05007990 - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT04903496 - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Recruiting NCT05294822 - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Completed NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4